Advertisement
Screener

Dare Bioscience, Inc. (DARE) Adjustments to Additional Paid in Capital, Warrant Issued

1.6 / 5 stars · 20/62 Roast Me

Dare Bioscience, Inc. Adjustments to Additional Paid in Capital, Warrant Issued

Dare Bioscience, Inc. (DARE) reported Adjustments to Additional Paid in Capital, Warrant Issued of $182.98 thousand for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-12.

Financial Statements › Adjustments to Additional Paid in Capital

us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued · last filed 2025-03-31

  • Dare Bioscience, Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2024-06-30 was $182.98K, a 59.54% decline year-over-year.
  • Dare Bioscience, Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2024-03-31 was $215.11K, a 83.44% decline year-over-year.
  • Dare Bioscience, Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2023-09-30 was $8.11M.
  • Dare Bioscience, Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2023-06-30 was $452.19K, a 62.90% decline year-over-year.
  • Dare Bioscience, Inc. adjustments to additional paid in capital, warrant issued for fiscal 2023 was $834.51K, a 31.53% decline from fiscal 2022.
  • Dare Bioscience, Inc. adjustments to additional paid in capital, warrant issued for fiscal 2022 was $1.22M, a 143.68% increase from fiscal 2021.
  • Dare Bioscience, Inc. adjustments to additional paid in capital, warrant issued for fiscal 2021 was $500.15K, a 72.00% decline from fiscal 2020.
  • Dare Bioscience, Inc. adjustments to additional paid in capital, warrant issued for fiscal 2020 was $1.79M.
Period endAdjustments to Additional Paid in Capital, Warrant Issued 3 monthAdjustments to Additional Paid in Capital, Warrant Issued 6 monthAdjustments to Additional Paid in Capital, Warrant Issued 9 monthAdjustments to Additional Paid in Capital, Warrant Issued 12 month
2024-06-30$182.98K
10-Q · filed 2024-08-12
$398.09K
derived: sum of 2 quarters · filed 2024-08-12
2024-03-31$215.11K
10-Q · filed 2024-08-12
2023-12-31$834.51K
10-K · filed 2025-03-31
2023-09-30$8.11M
10-Q · filed 2023-11-09
$8.56M
derived: sum of 2 quarters · filed 2024-08-12
$9.86M
derived: sum of 3 quarters · filed 2024-08-12
2023-06-30$452.19K
10-Q · filed 2024-08-12
$1.75M
derived: sum of 2 quarters · filed 2024-08-12
2023-03-31$1.30M
10-Q · filed 2024-08-12
2022-12-31$1.22M
10-K · filed 2024-03-28
2022-06-30$1.22M
10-Q · filed 2023-11-09
2021-12-31$500.15K
10-K · filed 2023-03-30
2021-09-30$204.47K
10-Q · filed 2022-11-10
2021-03-31$50.40K
10-Q · filed 2022-11-10
2020-12-31$1.79M
10-K · filed 2022-03-31
2020-09-30$120.96K
10-Q · filed 2021-11-10
2020-03-31$1.67M
10-Q · filed 2021-11-10
2014-06-30$424.00K
10-Q · filed 2015-08-06

Similar stocks

Stock NameCountryMarket CapPE Ratio
KIORA PHARMACEUTICALS INC (KPRX)United States$0.012B
Scienture Holdings, Inc. (SCNX)United States$0.012B-0.38
Phio Pharmaceuticals Corp. (PHIO)United States$0.012B-0.92
ADIAL PHARMACEUTICALS, INC. (ADIL)United States$0.012B
Moleculin Biotech, Inc. (MBRX)United States$0.011B
MetaVia Inc. (MTVA)United States$0.011B-0.65
KALA BIO, Inc. (KALA)United States$0.011B-3.33
BIOVIE INC. (BIVI)United States$0.012B
Theriva Biologics, Inc. (TOVX)United States$0.011B
Aspire Biopharma Holdings, Inc. (ASBP)United States$0.012B-0.60